Provided by Tiger Trade Technology Pte. Ltd.

iShares Neuroscience and Healthcare ETF

31.75
+0.36081.15%
Volume:2K
Turnover:77.04K
Market Cap:6.35M
PE:- -
High:31.87
Open:31.87
Low:31.75
Close:31.39
52wk High:43.01
52wk Low:27.40
Shares:200.00K
Float Shares:200.00K
Volume Ratio:1.25
T/O Rate:1.21%
Dividend:0.32
Dividend Rate:1.00%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Scholar Rock Holding Price Target Raised to $70.00/Share from $64.00 by Wedbush

Dow Jones
·
Sep 15

Scholar Rock Holding Corporation : H.c. Wainwright Raises Target Price to $70 from $65

THOMSON REUTERS
·
Sep 15

Brain-Computer Breakthrough Enables Paralysed Individuals to Communicate Through Digital Avatars

Deep News
·
Sep 15

Market Playbook: Key Bullish and Bearish Signals for Stocks on September 15, 2026

Deep News
·
Sep 15

Scholar Rock downgraded to Equal Weight from Overweight at Barclays

TIPRANKS
·
Sep 15

Kestra Medical Technologies Q1 Revenue Beats Estimates, Raises FY Revenue Outlook

Reuters
·
Sep 15

Scholar Rock Says Its First Muscle-Targeted SMA Therapy Will Cost About $310,000 Annually

Reuters
·
Sep 14

Scholar Rock Holding Price Target Maintained with a $64.00/Share by Wedbush

Dow Jones
·
Sep 14

U.S. Stocks on the MOVE-US Energy Stocks, Baldwin, Johnson & Johnson

Reuters
·
Sep 14

Scholar Rock Exec Says Its First Drug to Target Muscle Loss in Spinal Mus­Cu­Lar at­Ro­Phy Has a Wholesale Acquisition Cost of $11,659 for a Single Use Vial - Conf.call

THOMSON REUTERS
·
Sep 14

Scholar Rock Exec Says Co Expects the Annual Net Cost in the U.S. for a Typical Patient to be Approximately $310,000

THOMSON REUTERS
·
Sep 14

Scholar Rock price target raised to $84 from $76 at BMO Capital

TIPRANKS
·
Sep 14

Top Premarket Gainers

MT Newswires Live
·
Sep 14

Truist Raises Price Target on Scholar Rock Holding to $76 From $55, Keeps Buy Rating

MT Newswires Live
·
Sep 14

Scholar Rock Shares up 11.6% Premarket After FDA Nod for First Muscle-Targeted Drug for Type of Genetic Disease

THOMSON REUTERS
·
Sep 14

Scholar Rock Holding Corporation : Citigroup Raises Target Price to $74 from $60

THOMSON REUTERS
·
Sep 14

Scholar Rock Gets FDA Approval for Spinal Muscular Atrophy Treatment in Children, Adults; Shares Up Pre-Bell

MT Newswires Live
·
Sep 14

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), Scholar Rock Holding (SRRK) and Danaher (DHR)

TIPRANKS
·
Sep 14

Scholar Rock announces FDA approval of isembyld

TIPRANKS
·
Sep 12

FDA Approves Scholar Rock’s Isembyld for Spinal Muscular Atrophy Patients Aged 2 and Older on SMN2 Therapy

Reuters
·
Sep 12